Biogen / PMNThis is what Promis was and is all about, a therapeutic for misfolded proteins and Dr.Cashmans dream and validated science to get this to the finish line. What plagues us more then anything is bad management and ridiculous financings. Now we have Biogen again increasing their market cap by about 40 Billion dollars and Promis being held down by an existing financing at 12 cents. Anybody can see this is bad timing and a ridiculous financing at a ridiculous price. Continuous discussions with Goldstein has amounted to landing on deaf ears, he thinks he knows better then anyone, but he does not. He treats this like a private Company and does whatever he wants. I have been here the longest and know more about the history of this Company then anyone and I can tell you Elliott must resign, he is a disaster for this Company. A small Biotech paying fees of 1 million Dollars a year is to say the least crazy. I am hopeful we can joint venture PMN310 with a bigger pharmaceutical and get this to clinical. Positive news from the FDA should get suitors to adopt abeta amyloids as a path forward. Totally dissapointed with this Board.